Navigating the Frontier of Hematologic Malignancy Therapies (5 of 5 Modules)
This activity provides an overview of recent data supporting the potential utility of circulating tumor DNA to predict risk and inform personalized therapeutic decision making for patients with lymphoma.
Upon completion of this activity, participants should be better able to:
Clinical Director, Lymphoid Malignancies Branch
Center for Cancer Research
National Cancer Institute, NIH
Bethesda, MD
Professor, Departments of Medicine and Pediatrics
Director, Center for Cell and Gene Therapy
Dan L. Duncan Chair
Interim Director, Dan L. Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, TX
Lead Scientist, Department of Cancer Biology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA
Full Member, Fred Hutchinson Cancer Center
Professor, Pediatrics
University of Washington
Seattle, WA
Featured RMEI CE Activities – Earn CE Credit(s)
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources
